Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March
2019
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
29
March 2019
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE NOT FOR
RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY JURISDICTION IN
WHICH THE SAME WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS NOT AN OFFER
OF SECURITIES IN THE UNITED STATES, CANADA, SOUTH AFRICA,
AUSTRALIA, JAPAN OR ANY JURISDICTION IN WHICH THE SAME WOULD BE
UNLAWFUL.
Results of Placing
AstraZeneca
PLC (the "Company" or
"AstraZeneca") is
pleased to announce the successful completion of the placing
announced earlier today (the "Placing").
A total
of 44,386,214 new ordinary shares of twenty-five cents each in the
Company (the "Placing Shares")
have been placed at a price of £60.50 per Placing Share (the
"Placing
Price"), raising proceeds of approximately £2.69
billion ($3.5 billion at a GBP:USD average exchange rate of 1.3034)
(before expenses). The Placing Shares being issued represent
approximately 3.5 per cent. of the issued ordinary share capital of
the Company.
The
Placing Price of £60.50 each represents a discount of 1.5 per
cent. to the middle market price at the time at which the Company
agreed the Placing Price and complies with the guidance set out in
the 'Statement of Principles' in respect of the disapplication of
pre-emption rights issued by the Pre-Emption Group in 2015. The
Placing Shares, when issued, will be credited as fully paid and
will rank pari passu in all respects with the existing ordinary
shares of twenty-five cents each in the capital of the Company,
including the right to receive all dividends and other
distributions declared, made or paid on or in respect of such
shares after the date of issue.
Applications
have been made for admission of the Placing Shares to the premium
listing segment of the Official List of the Financial Conduct
Authority (the "Official List") and
to trading on the main market of the London Stock Exchange plc
(together, "Admission"). It is
expected that settlement for the Placing Shares and Admission will
take place at 8.00 a.m. on 2 April 2019. Settlement of the Placing
is conditional upon, amongst other things, Admission becoming
effective and upon the placing agreement not being terminated in
accordance with its terms.
Following
Admission the total number of shares in issue in the Company will
be 1,311,755,099.
END
About AstraZeneca
AstraZeneca
is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three therapy
areas - Oncology, Cardiovascular, Renal & Metabolism and
Respiratory. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
For more information, please
visit astrazeneca.com and
follow us on Twitter@AstraZeneca.
|
Media Relations
|
|
|
|
Gonzalo
Viña
|
UK/Global
|
+44 203
749 5916
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Matt
Kent
|
UK/Global
|
+44 203
749 5906
|
|
Jennifer
Hursit
|
UK/Global
|
+44
203 749 5762
|
|
Christina
M Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Christer
Gruvris
|
BioPharma
- Cardiovascular; Metabolism
|
+44 203
749 5711
|
|
Nick
Stone
|
BioPharma
- Respiratory; Renal
|
+44 203
749 5716
|
|
Josie
Afolabi
|
Other
|
+44 203
749 5631
|
|
Craig
Marks
|
Finance;
Fixed Income
|
+44
7881 615 764
|
|
Jennifer
Kretzmann
|
Retail
Investors; Corporate Access
|
+44 203
749 5824
|
|
US
toll-free
|
|
+1 866
381 72 77
|
|
|
|
|
For further information:
All
news releases can be accessed at our web site:
https://www.astrazeneca.com/investor-relations/stock-exchange-announcements.html
Important Information:
These
materials do not contain or constitute an offer or sale or the
solicitation of an offer to purchase securities in the United
States. The securities referred to herein have not been and will
not be registered under the United States Securities Act of 1933
(the "Securities Act"),
and may not be offered or sold in the United States absent
registration under the Securities Act or an available exemption
from, or transaction not subject to, the registration requirements
of the Securities Act.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
29 March
2019
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|